Skip to content

Observational Study of DME Following Scatter Laser Photocoagulation

An Observational Study of the Development of Diabetic Macular Edema Following Scatter Laser Photocoagulation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00687154
Acronym
PRP
Enrollment
155
Registered
2008-05-30
Start date
2005-09-30
Completion date
2008-01-31
Last updated
2016-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema

Keywords

DME, Laser, macular edema, retinopathy, scatter photocoagulation

Brief summary

The development or worsening of macular edema following full scatter photocoagulation is a well recognized occurrence. However, there is limited literature in this regard. The purpose of this study is to determine the incidence and extent of macular edema following scatter laser photocoagulation surgery using optical coherence tomography (OCT) in eyes without macular edema prior to scatter laser photocoagulation and to explore whether the incidence and extent of macular edema varies according to the number of sittings included in the treatment regimen. Study eyes will receive one of two types of scatter photocoagulation with results compared through use of OCT and photography images, as well as visual acuity testing.

Detailed description

Study eyes will receive scatter photocoagulation given by one of the following two regimens. To reduce selection bias, investigators will be required, prior to study initiation, to indicate which treatment (1 PRP sitting or 4 PRP sittings) they will administer. Only the selected treatment will be performed by a given investigator on study eyes. * 1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator. * 4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns. Both of these regimens conform with usual clinical practice. The study aims to enroll 150 eyes. At least 40 eyes will be enrolled with prior focal laser photocoagulation and at least 40 eyes without prior focal laser treatment. After enrollment of 80 eyes (40 with prior treatment and 40 without prior treatment), an interim analysis will be conducted so that focused enrollment strategies can be implemented if the analysis suggests that more subjects in a subgroup should be entered. Approximately half of the eyes will receive each scatter treatment regimen. The following procedures will be done on the study eye at baseline and at each scheduled visit (except 8 and 12 weeks at which exam data are not collected) unless otherwise specified: * OCT * E-ETDRS visual acuity in both eyes (refraction in the study eye at baseline, 17 weeks, and 34 weeks) * Fundus photographs (7-fields at baseline and 3-fields at 34 weeks only) * Photographs to document the scatter photocoagulation (day of the first PRP sitting only)

Interventions

PROCEDUREScatter Laser Photocoagulation in 1 Sitting

1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.

PROCEDUREScatter Laser Photocoagulation in 4 Sittings

4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.

Sponsors

National Eye Institute (NEI)
CollaboratorNIH
Jaeb Center for Health Research
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

To be eligible, the following inclusion (1-4) and

Exclusion criteria

(5-8) must be met: 1. Age \>= 18 years • Patients \<18 years old are not being included because there would be an insufficient number of patients \<18 years old who would meet eligibility criteria for the study in order to be able to generalize the results to patients \<18 years old or to provide informative data as to the effects of treatment in this age group. 2. Diagnosis of diabetes mellitus (type 1 or type 2) • Any one of the following will be considered to be sufficient evidence that diabetes is present: 1. Current regular use of insulin for the treatment of diabetes 2. Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes 3. Documented diabetes by ADA and/or WHO criteria 3. At least one eye meets the study eye criteria listed in section 2.2.2. 4. Able and willing to provide informed consent.

Design outcomes

Primary

MeasureTime frame
Retinal thickening (measured with OCT)34 weeks

Secondary

MeasureTime frame
Visual Acuity (measured with E-ETDRS)2 days, 4 weeks, 17, and 34 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026